Cadence Pharmaceuticals Reports Second Quarter 2007 Financi...(CALS INC. (a deve...)

(a development stage company)

CONDENSED STATEMENTS OF OPERATIONS

(unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

2007 2006 2007 2006

Operating expenses:

Research and

development $12,754,991 $4,928,724 $20,996,795 $33,663,970

Marketing 466,354 220,783 768,537 316,541

General and

administrative 2,435,940 1,430,631 4,263,532 1,967,980

Total

operating

expenses 15,657,285 6,580,138 26,028,864 35,948,491

Loss from

operations (15,657,285) (6,580,138) (26,028,864) (35,948,491)

Other income, net 722,696 381,333 1,534,577 508,606

Net loss $(14,934,589) $(6,198,805) $(24,494,287) $(35,439,885)

Basic and diluted

net loss per

share(1) $(0.52) $(4.92) $(0.86) $(28.50)

Shares used to

compute basic and

diluted net loss

per share(1) 28,546,033 1,260,132 28,475,594 1,243,500

(1) As a result of the issuance of 6,900,000 shares of common stock in

the Company's initial public offering in the fourth quarter of 2006

and the conversion of the Company's preferred stock into 19,907,605

shares of common stock upon completion of the Company's initial

public offering, there is a lack of comparability in the basic and

diluted net loss per share amounts for the periods presented above.

CADENCE PHARMACEUTICALS, INC.

(a development stage company)

CONDENSED BALANCE SHEET
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc. Copyright©2007 PR Newswire.

0 GOOD